Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 175378, 5 pages
http://dx.doi.org/10.1155/2014/175378
Clinical Study

Evaluation of the Effectiveness of the Iralvex Gel on the Recurrent Aphthous Stomatitis Management

1Dental Material Research Centre and Department of Oral Medicine, School of Dentistry, Isfahan University of Medical Sciences, Hezar-Jerib Avenue, Isfahan 8174673461, Iran
2Dental Students’ Research Center, School of Dentistry, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
3Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran

Received 27 April 2014; Accepted 23 July 2014; Published 14 October 2014

Academic Editor: Tzi Bun Ng

Copyright © 2014 Heidar Khademi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. As there is no definitive treatment for the recurrent aphthous stomatitis (RAS), most of the available therapies aim at decreasing pain and discomfort. The aim of this study was to investigate the effectiveness of the Iralvex gel on the RAS management. Material and Methods. In this double-blind and placebo-controlled clinical trial study, twenty patients were treated with the Iralvex gel and the other twenty patients were treated with placebo. In every participant complete healing of lesions, pain duration, and intensity were evaluated. Data were analyzed by independent t-test and analysis of variance. Results. Pain was relieved after 6.10 ± 0.29 days in the Iralvex group in comparison to 8.00 ± 0.33 days in the placebo group (P value ≤0.001). Complete remission in the Iralvex group was after 6.80 ± 0.27 days and 10.20 ± 0.42 days in the placebo group ( value ≤ 0.001). Furthermore, significant differences in the pain intensity between Iralvex and placebo group measured on days 1, 3, and 5 were obtained ( value ≤ 0.01). Conclusion. The results of this study show that Iralvex gel is effective and cheap remedy for treatment of RAS without side effects. This trial is registered with IRCT201207253251N3.